For obesity treatment, dose escalation protocols starting at lower doses (e.g., 2 mg) and gradually increasing to maintenance doses (e.g., 4 mg, 8 mg, or 12 mg) have been studied Link below for more detailed information: Product Overview: Retatru/Cagrilintide is a dual-compound research peptide combining Retatru, a novel multi-agonist peptide with activity across GLP-1, GIP, and glucagon pathways, and Cagrilintide, an amylin analog
Elevated NNMT is a consistent feature in obesity research across species, making it a key area of preclinical investigation
Achilles chronic tendinitis is characterized by pain at posterior aspect of ankle on both sides of tendon
GLP-3 (Reta) is not currently named on the WADA 2026 Prohibited List
Lyophilized powder before reconstitution can be frozen for long-term storage